Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of ≥300/mm3: CPCRA 059

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue 3, 2002, Pages 221-231

  Abrams, Donald I ^a   Bebchuk, Judith D ^a   Denning, Eileen T ^a   Davey, Richard T ^a   Fox, Lawrence ^a   Lane, H Clifford ^a   Sampson, James ^a   Verheggen, Rita ^a   Zeh, Douglas ^a   Markowitz, Norman P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dose; Immune modulator; Interleukin 2; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0036500935     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200203010-00002     Document Type: Article

References (35)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Changing patterns of mortality across Europe in patients infected with HIV-1
3. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study
4. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
5. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
6. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
7. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
8. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis
9. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-injected patients who have a response to antiretroviral therapy
10. 1999 USPHS/DSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
11. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
12. Interleukin-2: Inception, impact and implications
13. Interleukin-2 enhances the depressed natural killer cell and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome
14. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus
15. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine
16. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: A preliminary study
17. 3: Results of a randomized, controlled trial
18. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons
19. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients
20. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial
21. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with <250/μL CD4 T cells and undetectable plasma virus load
22. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection
23. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection
24. 3
25. A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 (IL-2) in HIV-1-infected patients in Thailand
26. Meta-analysis of the CD4 cell response to 3 doses of subcutaneous interleukin-2 (scIL-2) across 3 vanguard studies
27. Pooled analysis of 3 randomized controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
28. Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression
29. Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration
30. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
31. Effect of intefieukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active antiretroviral therapy
32. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial
33. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells
34. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha